Quick Heal Quick Heal Technologies Ltd.

Security Simplified (Formerly Known as Quick Heal Technologies Pvt. Ltd.) Regd. Office: Marvel Edge,Office No.7010,C& D, 7th Floor,opp. NECO Garden Society, Vimannagar, Pune - 411014 Tel:020-668132321 Email: [email protected] CIN- L72200MH1995PLC091408

Ref No.: QHTL/Sec/SE/2019-20/46 August 08, 2019

The Manager, Corporate Services, BSELimited, 14th floor, PJTowers, Dalal Street, Mumbai - 400 001 Ref: Security ID : QUICKHEAL Security Code: 539678

The Manager, Corporate Services, National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400051 Symbol: QUICKHEAL Series : EQ

Subject: Outcome of Board Meeting August 08,2019

Dear SirI Madam,

We wish to inform you that the Board of Directors at its meeting held on August 08, 2019 which commenced at 02.30 PM and concluded at 8:03 PM, has approved following:

• 1. Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2019.
• 1. A copy of the Press Release being issued in respect of aforesaid financial results.
• 1. A Presentation in respect of aforesaid financial results
• 1. Pursuant to Regulation 33 of SEBI Regulations, we have enclosed herewith Limited Review Report for the un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2019, from our Statutory Auditors, Mis MSKA & Associates, Chartered Accountants.

This is for your information and records.

For Quick Heal Technologies Limited

A. Srinivasa Rao Company Secretary

Encl: As Above

QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408

	STATEMENT OF CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES	LIMITED AND ITS SUBSIDIARIES		FOR THE QUARTER ENDED JUNE 30, 2019
					(INR in million, except per share data
			Ouarter ended		Year ended
Sr. No	Particulars	June 30, 2019 (Unaudited)	March 31, 2019 (Audited)	June 30, 2018 (Unaudited)	March 31, 2019 (Audited)
I	Income
	Revenue from operations	576.00	860.0\	530.88	3,149.26
	Other income	84.46	85.15	64.09	326.67
	Total income	660.46	945.16	594.97	3,475.93
	2 Expenses
	Cost of raw materials conswned	6.17	11.42	5.32	30.56
	Purchase of security software products	8.27	33.98	18.54	115.96
	Changes in inventories of security software products	3.60	(9.58)	(8.17)	(19.40)
	Employee benefits expense	266.32	239.59	254.77	988.51
	Depreciation and amortisation expense	51.63	56.32	59.22	235.49
	Other expenses	163.40	198.39	171.18	754.62
	Total expenses	499.39	530.12	500.86	2,105.74
	3 Profit I (loss) before exceptional items and tax (1-2)	161.07	415.04	94.11	1,370.19
4	Exceptional items	-	-	-	-
	5 Profit I (loss) before tax (3-4)	161.07	415.04	94.11	1,370.19
	6 Tax expense
	Current tax
	Pertaining to profit for the current period	41.78	146.99	29.75	447.25
	Adjustments of tax relating to earlier periods	-	31.28	-	45.99
	Deferred tax	0.31	(40.70	3.24	(41.29)
	Total tax expense	42.09	137.57	32.99	451.95
7	Profit I (loss) for the period (5-6)	118.98	277.47	61.12	918.24
	8 Other comprehensive income, net of tax
	Other comprehensive income not to be reclassified to profit or loss in subsequent periods:
	Re-measurement of defined benefit plans	3.96	0.42	(4.69)	(3.23)
	Net (loss) or gain on FVTOCI assets	-	-	-	(29.52)
	Exchange differences on translation of foreign operations	(1.32)	0.17	2.30	2.73
	Total other comprehensive income	2.64	0.59	(2.39)	(30.02)
	9 Total comprehensive income (after tax) (7+8)	121.62	278.06	58.73	888.22
	10 Paid-up equity share capital (face value ofINR 10 each)	642.01	705.63	704.70	705.63
II	Other equity (as per balance sheet of previous accounting year)				7,191.79
	12 Earnings per share of INR 10 each: (not annualised for the quarter)
	a) Basic	1.70	3.94	0.87	13.03
	b) Diluted	1.70	3.94	0.87	13.02

	QIDCK HEAL TECHNOLOGIES LIMITED
	Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014
	CIN: L72200MH1995PLC091408
	NOTES TO THE STATEMENT OF CONSOLIDATED FINANCIAL RESULTS OF QIDCK HEAL TECHNOLOGIES LIMITED AND ITS SUBSIDIARIES FOR THE QUARTER ENDED JUNE 30. 2019
	Notes to financial results:
liThe	above financial results for the quarter ended June 30, 2019 have been subjected to limited review by the statutory auditors of the Group and reviewed by the Audit Committee and approved by the Board of Directors of the Group at the meeting held on August 08, 2019.
	2 IIn accordauce with the SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018 dated May 09,2018 the company has prepared and published the quarterly consolidated financial results for the first time for the quarter ended June 30, 2019. Thus, the quarterly financial results reported above for the quarter ended June 30, 2018 and quarter ended March 31, 2019 were not subjected to limited review.
	3 [During the previous year ended March 31, 2019, the Group has received notice of demand dated March 13,2019, in relation to service tax under the provisions of Finance Act, 1994 for INR 387.43 million (excluding interest and penalties) covering the period from April I, 2016 to June 30, 2017 on supply of anti-virus software in Compact Disk. The Group has replied the notice of demand to Commissioner of Goods and Service Tax, Pune.
	During the earlier years, the Group had similarly received notice of demands in relation to service tax under the provisions of Finance Act, 1994 for INR 1,223.07 million (excluding penalty of INR 626.97 million and predeposit, if any) covering the period from March 1,2011 to March 31, 2016 on supply of anti-virus software in Compact Disk. The Group had filed an appeal with Customs, Excise and Service Tax Appellate Tribunal, New Delhi for the period March 1,2011 to March 31, 2014 and with the Customs, Excise and Service Tax Appellate Tribunal, Mumbai for the period April I, 2014 to March 31, 2016.
	Based on technical circular issued by government authorities and an independent legal opinion obtained by the Group in earlier years, the Group is of the view that the said claim would be set aside. Accordingly no provision (including interest and penalty) has been recognised and the demand has been disclosed as contingent liability in the financial statements.
	4 IEfTective April I, 2019, the Group has adopted Ind AS 116 "leases". The application oflnd AS 116 did not have any material impact on the financial results of the Group.
5	The Board of Directors of the Group at its meeting held on March 5, 2019 and the shareholders by way of postal ballot on April 13, 2019, approved the buy back of the Parent Company fully paid equity shares of the face value ofINR 10 each from its shareholderlbeneficial owners of equity shares of the Quick Heal Technologies Limited (parent Company) including promoters and promoter group of the Parent Company as on the record date, on a proportionate basis through the "tender offer" route a: a price of lNR 275 per share for an aggregate amount not exceeding lNR 1,750 million. The Parent Company completed the Buy Back Process in June 2019 and has complied with all the requisite formalities with SEBI and ROC
	In accordauce with section 69 of the Companies Act, 2013, during the three months ended June 30, 2019, the Group has created 'Capital Redemption Reserve' of lNR 63.64 million equal to the nominal value of the shares bought back as an appropriation from Securities Premium Account
	6 [The Group is engaged in providing security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. retail, enterprise & government and mobile. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Group has structured its operations into one operating segment viz. anti-virus and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
	7 IMr. Pradeep V Bhide resigned as Independent Director of the Parent Company w.e.f. April 01, 2019. Mr. Manu Parpia resigned as Independent Director of the Parent Company w.e.f. May 11,2019.
	8 [Figures for the quarter ended March 31, 2019 arc the balancing figures between the audited figures of the financial year ended March 31, 2019 and unaudited and non reviewed figures for the nine month ended December 31, 2018.
	For .i::1~ofth~tors
	~ s•• [ay •••• r Place: Pune Joint Managing Director
	& Chief Technology Officer Date: August 08, 2019

I	QUICK HEAL TECHNOLOGIES Regd. Office: Marvel Edge, Office No. 7010 C 8< D, 7th Floor, Opposite Neeo Garden Society, Vlman Nagar, Pune - 411014 C"JN: L 72200MHI995PLC'091408	LIMITED
	STATEMENT OF STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES		LIMITED FOR TIlE QUARTER ENDED JUNE 30, 2019
			Quarter ended		(INR In million except per share data Year ended
Sr. No	Particulan	June 30, 2019 nlnaudlted!	March 31, 2019 (Audited!	June 30,2018 fUnaudltedl	March 31, 2019 (Audited)
I	Income
	Revenue from operations Other income	571.49	853.54 84.80	527.88	3,129.03
	Total income	84.27 655_76	938.34	63.75 591.63	325.00 3454.03
	2 Expenses Cost of raw materials consumed	6.18	8.78	1.80	29.51
	Purchase of security software products	8.27	31.34	19.22	114.26
	Increase I (decrease) in inventories of security software products	3.87	(4.26)	(2.94)	(14.84)
	Employee benefits expense	264.13	235.75	250.87	971.38
	Depreciation and amortisation expense	51.61	56.27	59.14	235.27
	Other expenses	158.91	192.75	166.20	734.58
	Total expenses	492.91	520.63	494.29	2,010.16
	3 Profit before exceptional Items and tax (1-2)	162.19	411.11	91.34	1,383.87
	4 Exceptional items (refer note 4)	-	43.11		93.17
	5 Profit before tn (34)	162.19	374.54	91.34	1,290.70
	6 Tax expense
	Currenttax
	Pertaining to profit for the current period	41.62	146.70 31.28	29.69	446.36
	Adjustments of tax relating to earlier periods (Net) Deferred tax	0.31	(40.70	3.24	45.99 (41.29
	Total tax expense	41.93	137.28	32.93	451.06
	7 Profit for the period (5-6)	120.86	237.26	64.41	839.64
	8 Other comprehensIve Income, net of tax
	Other comprehensive Income not to be reclassified to profit or loss In subsequent periods:
	Re-measurement of defined benefit plans	3.96	0.42	(4.69)	(3.23)
	Net (loss) or gain on FVTOCI assets (refer note 4)	-	-	-	(29.52)
	Other comprehensive Income to be reclassified to proflt or toss In subsequent periods:
	Exchange differences on translation of foreign operations	-			-
	Total other comprehensive income	3.96	0.42	(4.69)	(32.75)
	9 Total comprehensive Income (after tu) (7+8)	124.82	237.68	59.72	806.89
	10 Paid-up equity share capital (face value ofINR 10 each)	642.01	705.63	704.70	705.63
II	Other equity (as per balance sheet)				7,243.12
	12 Earnings per share of INR 10 each: (not annualised except for the year ended March)
	a) Basic b) Diluted	1.73 1.73	3.37 3.37	0.91 0.91	11.91 11.90

	QUICK HEAL TECHNOLOGIES LIMITED Regd, Omce: Marvel Edge, Offlee No. 7010 C & D, 7th Floor, Opposite Neeo Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408
	NOTES TO THE STATEMENT OF STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES	LIMITED FOR THE QUARTER	ENDED JUNE 30 2019
	Notes to finanelal results:
	1 The above financial results for the quarter ended June 30, 20 i 9 have been subjected to limited review by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held 00 August 08, 2019.
	2 During the previous year ended March 3i, 2019, the Company has received notice of demand dated March i3, 20i9, in relation 10 service tax under the provisions of Finance Act, i994 for INR 387.43 million (excluding interest and penalties) covering the period from April 1. 2016 to June 30,2017 on supply of anti- virus software in Compact Disk. The Company has replied the notice of demand to Commissioner of Goods and Service Tax, Pune.
	During the earlier years, the Company had similarly received notice of demands in relation 10 service tax under the provisions of Finance Act, 1994 for INR 1,223.07 million (excluding penahy ofINR 626.97 ntillion and predeposit, if any) covering the period from March 1,2011 to March 31, 2016 on supply of anti-virus software in Compact Disk. The Company had filed an appeal with Customs, Excise and Service Tax Appellate Tribunal, New Delhi for the period March I, 2011 10 March 31, 2014 and with the Customs, Excise and Service Tax Appellate Tribunal, Mumbai for the period April I. 201410 March 31,2016.
	Based on technical circular issued by government authorities and an independent legal opinion obtained by the Company in earlier years, the Company is of the view that the said claim would be set aside. Accordingly no provision (including interest and penalty) has been reccgnised and the demand has been disclosed as contingent liability in the financial statements.
	3 Effective April 1, 2019, the Company has adopted Ind AS 116 "leases" The application ofind AS 116 did not have any material impact on the financial results of the Company.
	4 Impairment of Investments Included in exceptional items				IlNR In million)
	Partieulan			Standalone
			Quarter ended		Yeareaded
		June 30,2019	March 31, 2019	June 30, 2018	Marc~ 31, 2019
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Impainnent of investment in wholly owned subsidiaries Further, the decline in fair value of investment ofINR Nil million (March 31,2019: INR 29.52 million) has been included in Other Comprehensive income.		43.17		93.17
	The Board of Directors of the Company at its meeting held on March 5. 2019 and the shareholders by way of postal ballot on April 13. 2019. approved the buyback of the Company fully paid equity shares of the face value oflNR 10 each from its sharebolderlbeneficial owners of equity shares of the Company including promoters and promoter group oCthe Company as on the record date, on a proportionate basis through the "tender offer" route at a price ofINR 275 per share for an aggregate amount not exceeding INR 1,750 million. The Company completed the Buy Back Process in June 2019 and has complied with all the requisite formalities with SEBI and ROC In accordance with section 69 of the Companies Act, 2013, during the three months ended June 30, 2019, the Company has created 'Capital Redemption Reserve' of INR 63.64 million equal to the nominal value of the shares bought back as an appropriation from Securities Premium Account
	6 The Company is engaged in providing security software solutions. The Chief Operating Decision Maker (COOM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. retail, enterprise & government and mobile. However, based on risk and reward structure, organisation structure and internal reporting systems, the Company has structured its operations into one operating segment viz. anti-virus and as such there is no separate reportable operating segment as defined by Ind similarity of activities/products, AS 108 "Operating segments".
	7 Mr. Pradeep V Bbide resigned as Independent Director of the Company w.e.f April 01, 2019. Mr. Manu Parpia resigned as Independent Director of the Company w.e.f May II, 2019.
	8 Figures for the quarter ended March 31,2019 are the balancing fig= between the audited figures of the financial year ended March 31, 2019 and published year to date fig= of nine month ended December 31, 2018.
S				'(SZ.~.~-."-

	QUICK HEAL TECHNOLOGIES LIMITED
	Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014
	CIN: L72200MH1995PLC091408
	STATEMENT OF CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED AND ITS SUBSIDIARIES FOR THE QUARTER ENDED JUNE 30, 2019
					(INR in million, except per share data)
			Quarter ended		Year ended
Sr. No	Particulars	June 30, 2019	March 31, 2019	June 30, 2018	March 31, 2019
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
$\mathbf{1}$	Income
	Revenue from operations	576.00	860.01	530.88	3,149.26
	Other income	84.46	85.15	64.09	326.67
	Total income	660.46	945.16	594.97	3.475.93
$\overline{2}$	Expenses
	Cost of raw materials consumed	6.17	11.42	5.32	30.56
	Purchase of security software products	8.27	33.98	18.54	115.96
	Changes in inventories of security software products	3.60	(9.58)	(8.17)	(19.40)
	Employee benefits expense	266.32	239.59	254.77	988.51
	Depreciation and amortisation expense	51.63	56.32	59.22	235.49
	Other expenses	163.40	198.39	171.18	754.62
	Total expenses	499.39	530.12	500.86	2,105.74
$\overline{3}$	Profit / (loss) before exceptional items and tax (1-2)	161.07	415.04	94.11	1,370.19
$\overline{4}$	Exceptional items		÷	$\alpha$	×
5	Profit / (loss) before tax (3-4)	161.07	415.04	94.11	1,370.19
6	Tax expense
	Current tax
	Pertaining to profit for the current period	41.78	146.99	29.75	447.25
	Adjustments of tax relating to earlier periods	÷	31.28	÷.	45.99
	Deferred tax	0.31	(40.70)	3.24	(41.29)
	Total tax expense	42.09	137.57	32.99	451.95
$\overline{\phantom{a}}$	Profit / (loss) for the period (5-6)	118.98	277.47	61.12	918.24
8	Other comprehensive income, net of tax
	Other comprehensive income not to be reclassified to profit or loss in subsequent periods:
	Re-measurement of defined benefit plans	3.96	0.42	(4.69)	(3.23)
	Net (loss) or gain on FVTOCI assets				(29.52)
	Exchange differences on translation of foreign operations	(1.32)	0.17	2.30	2.73
	Total other comprehensive income	2.64	0.59	(2.39)	(30.02)
9	Total comprehensive income (after tax) (7+8)	121.62	278.06	58.73	888.22
10	Paid-up equity share capital (face value of INR 10 each)	642.01	705.63	704.70	705.63
11	Other equity (as per balance sheet of previous accounting year)				7,191.79
	12 Earnings per share of INR 10 each:
	(not annualised for the quarter)
	a) Basic	1.70	3.94	0.87	13.03
	b) Diluted	1.70	3.94	0.87	13.02

	Unaudited standalone financial information
	$(INR in million, except per share data)$
			Ouarter ended		Year ended
Sr. No.	Particulars	June 30, 2019	March 31, 2019	June 30, 2018	March 31, 2019
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	I Revenue from operations	571.49	853.54	527.88	3,129.03
	2 Profit before tax	162.79	374.54	97.34	1,290.70
	3 Profit after tax	120.86	237.26	64.41	839.64

	Note. to flnandal results:
	1 The above financial results for the quarter ended June 30,2019 have been subjcc:tc:dto limited review by the statutory auditors of the Group and reviewed by the Audit Conunittec and approved by the Board of Directors of the Group at the meeting held on August Og, 2019.
	In accordance with the SEBI (Listing Obliptions and Disclosure Requirements) (Amendmenu) Regulations, 2018 dated May 09, 2018 the company has prepared and published the quarterly consolidated financial results for the first timefor the quarter ended June 30, 2019. Thus, the quarterly financial results reponed above for the quaner ended June 30, 2018 and quarter ended March 31, 2019 WQ't not subjected to limited review.
	During the previous year ended March 31, 2019, the Group has received notice of demand dated March 13,2019, in relation to service tax under the provisions ofFinance Act, 1994 for INR 387.43 million (excluding interest and penalties) covering the period from April I, 2016 to June 30, 2017 on supply of anti-virus software in Compact Disk. The Group has replied the notice of demand to Commissioner of Goods and Service Tax, Pune.
	During the earlier years. the Group had similarly received notice of demands in relation to service tax under the provisions of Financc Act, 1994 for INR 1,223.07 million (excluding penalty oflNR 626.97 million andprcdeposit, if any) covering the period from March 1, 2011 to March 31, 2016 on eupplycf'anu-virus softwan: in Compact Disk. The Group had filed an appeal with Customs, Excise and Service Tax Appellate Tribunal, New Delhi for the period March 1,2011 to Marth 31, 2014 and with the Customs, Excise and Service Tax Appellate Tribunal, Mumbai for the period April 1, 2014 to March 31, 2016.
	Based 011 technical circular issued by government authorities and an independent legal opinion obtained by the Group in earlier years. the Group is of the view that the said claim would be set aside. Accordingly no provision (including interest and penalty) has been recognised and the demand has been disclosed u contingent liability in the financial statements.
•	Effective April I, 2019, the Group has adopted Ind AS 116 -Ieases-. Theapplicatioo ofind AS 116 did not have any material impact on the financial rcsulta of the Group.
	S The Board ofDirecton of the Group at ill meeting held on March 5, 2019 and the shareholdc:n by way of postal ballot on April 13,2019, approved the buy back of the Parent Company fully paid equity shares of the face value ofINR 10 each from its sh.areholderlbeneficial owners of equity shares of the Quick Heal Technologies Limited (parent Company) including promoters and promoter group of the Parent Company as on the record date, on a proportionate basis through the ''tender offer" route at I price ofINR 275 per share for an aggregate amount not exceeding INR 1,750 million. The Parent Company completed the Buy Back Process in June 2019 and has complied with all the requisite formalities with SEBI and ROC
6	The Group is engaged in providing security software solutions. The Chief Operating Decision Maker (COOM) reviews the information pertaming to revenue of each of the target CWItomergroup (segments) viz. retail, enterprise &. government and mobile. However, based on similarity ofactivitieslproducts, risk and reward structure, organisation structure and internal reporting systems, the Group has structured its operations into one operating segment viz. anti-virus and as such there is no separate reportable operating segment as defined by Ind AS 108 ''Operating segments".
	7 Mr. Pradeep V Bhide resigned as Independent Director of the Parent Companyw.e.f. April 01, 2019. Mr. Manu Parpiaresigned as Independent Dircctorofthe Parent Companyw.e.f. May 11,2019.
8	Figures for the quarter ended March 31, 2019 are the balancing figures between the audited figures of the financial year ended March 31, 2019 and unaudited and non reviewed figures for the nine month ended Dccemba3- 1,2018.
	F@raQaIlOf'b'BoardOfDlrectors
	~z
Place: Pune	JoInt Managing Director
	&. Chief Tecbnclegy Officer Date: August 08, 2019

FOR IMMEDIATE RELEASE

Quick Heal Technologies Limited announces Q1 FY20 results

PUNE, August 8, 2019: Quick Heal Technologies Limited ("Quick Heal"), India's leading provider of IT Security Software Products and Solutions to consumers, businesses and Government, reported its reviewed and unaudited results for the quarter ending 30th June 2019.

During the quarter, the overall demand for cybersecurity products and solutions in India was not in line with our expectations. We observed generic slowdown in demand which resulted in pricing pressure in the SMB and consumer segment. We also witnessed slowdown in Government buying due to India's General Elections. The performance highlights are as below:

Consolidated Financial Highlights:

Particulars (Rs. million)	Q1 FY20	Q1 FY19	YoY Change
Revenue	576.00	530.88	8.50%
EBITDA	128.24	89.24	43.70%
EBITDA Margin	22.26%	16.81%	+545 bps
PAT	118.98	61.12	94.67%
PAT Margin	20.66%	11.51%	+915 bps

Mr. Kailash Katkar, Managing Director & Chief Executive Officer, Quick Heal Technologies Limited,

said; "Despite sluggish economic scenario and moderate market growth, we are pleased to report steady growth for the quarter and kick start FY20 on a positive note. Our profit margins for the quarter have almost doubled, while our revenue has seen growth of 8.5% YoY. On the revenue front, retail segment grew by 8% with volume growth of 4%. Enterprise and Government business witnessed marginal growth of 2% on account of rising pricing pressure and slowdown in Government buying due to general election. However, volume growth for the segment stood at 7%. With growing importance of cybersecurity and data protection in India and globally, we expect better realisations and volume growth going forward."

Mr. Nitin Kulkarni, Chief Financial Officer, Quick Heal Technologies Limited, added "At Quick Heal, we have been continuously working on improving financial and operational efficiencies which reflects in our Q1 performance. Our growth in profitability is mainly attributable to changing product mix, strict cost optimization measures and focused research and development initiatives. During the quarter, we have concentrated on improving our collections which has resulted in lowering our receivable by Rs. 22 crores."

Mr. Vijay Mhaskar, Chief Operating Officer, Quick Heal Technologies Limited, commented "With constant focus on developing cutting edge products and solutions, we are happy to share that the company was granted a US Patent for our ground-breaking Anti-Ransomware technology. The patent approval

makes us the first Indian company to indigenously develop and granted a patent for Anti-Ransomware Technology. As cyber-threats continue to evolve in scale and sophistication, we will continue to innovate and deliver best-in-class protection against the rising menace of cybercriminals."

Segmental Performance for quarter ended 30 th June 2019

• Retail segment revenue up at Rs. 457 million as compared to Rs. 423 million in the corresponding period of the previous year
• Contributes 76% to Total Revenue
• Enterprise and Government segment revenue up at Rs. 146 million as compared to Rs. 144 million in the corresponding period previous year
• Contributes 24% to Total Revenue

Awards and Accreditations: -

Quick Heal Technologies Granted US Patent for Anti-Ransomware Technology by the United States Patent and Trademark Office (USPTO) (U.S. Patent No. US20160378988A1)

About Quick Heal Technologies Limited

Quick Heal Technologies Limited is one of the leading providers of IT security software products and solutions to individuals, businesses and Government. Incorporated in 1995 with a registered office in Pune, Quick Heal has a network of over 25,000 channel partners as on 30th June 2019. It conducts sales and marketing activities across India.

Quick Heal's portfolio includes solutions under the widely recognized brand names 'Quick Heal' and 'Seqrite' across various operating systems and devices.

For more information about the Company, please visit our website www.quickheal.co.in

Safe Harbor Statement

This document may contain forward-looking statements about Quick Heal Technologies Limited, which are based on the beliefs, opinions, and expectations of the company's management as the date of this press release and the companies do not assume any obligation to update their forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. Consequently, readers should not place any undue reliance on such forward-looking statements.

For further details please contact

Quick Heal Technologies Limited	Strategic Growth Advisors Pvt. Ltd.
CIN	CIN
No:	No:
L72200MH1995PLC091408	U74140MH2010PTC204285
Mr.	Mr.
Akash	Jigar
Gosavi	Kavaiya
Email	Email
Id:	Id:
[email protected]	[email protected]
Tel. No.: +91 020 6681 3287	Tel No: +91 992602034

Investor Presentation Q1 FY20

Safe Harbor

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Quick Heal Technologies Ltd. (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward-looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward- looking statements become materially incorrect in future or update any forward-looking statements made from time to time by or on behalf of the Company.

Journey over last two and half decades

Presence in B2C, B2B and B2G segments

Value Proposition

25 Years of Quick Heal Technologies…

…with a Vision & Mission

To be the trusted Global Leader in securing the Digital World

Secure our Customers by providing Innovative, most preferred and valued Security Solutions, Services and Knowledge

Protect information and interactions on all types of networks, devices & things globally

Build a healthy business and organization

…of offering Complete Security Solutions

18 ٠	× ٠

Platforms

...supported by Skilled Professionals

Research & Development Team

Working on identifying new threats and devising innovative solutions and features across retail, enterprise and mobile segments with more than 2 decades of experience

Sales and Marketing Team

Working closely with our customers and Channel Partners to identify new sales prospects, sell solutions and provide after-sales support.

Technical Support Team

Provide efficient multilingual and instant technical support, after sales service and effective guidance to domestic and overseas customers

…with strong Research & Development leading to Innovations

Ensures that we build the Right Products for the Right Markets at the Right Time Product Development Team Designing & building cutting edge products & solutions Quality Assurance Team Relentlessly maintaining and creating industry benchmarks for quality Incidence Response Team Ensures customers are unaffected by critical attacks/outages by responding promptly Security Labs Detect and analyze threat vectors across the globe and provide advanced protection to customers

Product Management Team

Internet of Things (IoT) Security Team

Creating solutions to ensure all your connected devices are secure

…striving for excellence in customer experience

…Sales & Distribution to increase Market Share

Established a robust & diversified network and a dynamic ecosystem of Channel Partners in cities & towns across India to reach our endcustomers

Strong internal Sales & Marketing

prospects, sell solutions and provide after-sales support

25,000+ Total Retail Partners

450+ Enterprise Partners

100+ Government Partners

Disclaimer: Maps not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness

…guided by Experienced Board of Directors

Drives the strategic direction for the company while nurturing a strong leadership team to drive its execution

Dr. KAILASH KATKAR MD & CEO

Spearheads the creation and subsequent development of the core product technology

Dr. SANJAY KATKAR Joint MD & CTO

Serves as the MD at Sequoia Capital India. Previously, he worked at Redknee's India subsidiary as the Managing Director

Mr. SHAILESH LAKHANI Non-Exe. Director

Serves as Director for RippleWave Equity Advisors LLP. Previously worked at JP Morgan, ICICI Securities and SEBI

Mr. MEHUL SAVLA Independent Director

Certified bank forensic accounting professional and anti – money laundering expert

Ms. APURVA JOSHI Independent Director

Has 20+ years of diverse experience in building and delivering a range of IT services for customers located across five continents

Ms. PRITI RAO Independent Director

Over three decades of experience in corporate finance, legal and litigation, strategy and M&A. Served as the Group CFO of Thermax

Mr. AMITABHA MUKHOPADHYAY Independent Director

… and Strong Leadership Team

… and Strong Leadership Team

Mr. Nagesh Ayyagari Vice President – Engineering, R&D

Seasoned technology professional with a reputation for building and inspiring high-performance teams that delivered inline with company

20+ years of experience in leadership positions at Mphasis Software, McAfee, and Oracle

Has management degrees from IIM, Bangalore and ESADE Business School & has done project management from UCB

Kuldeep Raina, Vice President, Global Enterprise Sales

Responsible for leading the enterprise and government sales strategy and managing the vertical on a global level

Passionate technocrat with a rich flare of selling with tenacity to drive targets in dynamic business environment

19+ years of diverse sales experience including leadership roles in IT Security companies

Mr. Deepak Mishra Head, Retail Sales

Responsible for enhancing market share and driving channel strategy for the retail brand

19+ years of experience in FMCG, Beverages, Telecom and IT Industries

Has extensive exposure in Sales and Distribution, channel management, and building a robust distribution to drive productivity and profitability

…giving Competitive edge Globally

Kenya	Colombia	South Korea
Australia	Panama	Sri Lanka
Macau	Venezuela	Thailand
Malaysia	Japan	Vietnam
New Zealand	Gambia	Poland
Qatar	Italy	Aruba
Singapore	Mauritius	France
Democratic Republic	Togo	Germany
Of The Congo	Uganda	Lithuania
Nigeria	Zambia	Mexico
South Africa	Bangladesh	Netherlands
United Arab Emirates	Cambodia	Paraguay
Iran	Hong Kong	Spain
Jordan	Myanmar	United States
Oman	Philippines

…certified by Global Agencies

...trusted by our Customers

"Our products help secure the endpoints, data and networks used by millions of customers"

Some of the industries we cater to:

…creating Specialized workforce at Quick Heal Academy

Academy Partners

Recent Developments

• Training for Faculty Members and School Students of Maharashtra Cosmopolitan Education Society.
• Conducted workshop on cyber security for college students.
• Designing online content for employees of a large corporate.

Savitribai Phule Pune University

Designed 'M-Tech in Information Security' Program for Savitribai Phule Pune University

Quantum University

MoU with Quantum University for a joint B.Tech (Hons.) with specialization in Cyber Security

Gujarat Forensic Sciences University

MoU with Gujarat Forensic Sciences University during Vibrant Gujarat 2017

Maharashtra Cosmopolitan Education Society

The society runs 30 institutes from its ultra modern campaigns located in Maharashtra

Chitkara University

MoU with Chitkara University

Introduced an additional stream in Cyber Security for the four-year Undergraduate program

Deen Dayal Upadhyaya College

MoU with Deen Dayal Upadhyaya College, a constituent college of the University of Delhi

…Awards and Accreditations as testimony to Innovation

• Quick Heal Total Security receives BEST+++ certification from AVLab
• Seqrite Endpoint Security: Best Overall Speed 2017: Silver Award for the Performance Test
• Seqrite Endpoint Security is Approved Corporate Endpoint Protection for Windows by AV-Test
• Approved Windows Security Product for year 2017 by AV-Comparatives
• Seqrite Endpoint Security is ICSAlabs certified product for year 2017

• Seqrite received Best Enterprise IT Security Brand award at 11th NCN innovative product award 2018
• Quick Heal Total Security (Windows) achieved one of the best protection rate in AV-Comparatives test
• Seqrite Endpoint Security certified as 'Approved Corporate Endpoint Protection' for Windows by 'AV-Test'
• Seqrite received best cybersecurity brand award at National Summit on Digital Innovation & Cybersecurity Summit

• Seqrite received the 'Best Performance 2018' award for its Endpoint Security Solution from AV-Test Institute in Germany
• Quick Heal granted Patent for Anti-Ransomware Technology U.S. Patent No. US20160378988A1

Product Offerings

Product Portfolio across Business Segments

Quick Heal Total Security

Quick Heal Internet Security

Quick Heal Antivirus Pro

Quick Heal Total Security For Mac

Quick Heal Antivirus for Server

Quick Heal PCTuner 3.0

Quick Heal Total Security Multi Device

Quick Heal Home Security

Seqrite Endpoint Security Seqrite Endpoint Security Cloud Seqrite UTM Seqrite mSuite Seqrite Encryption Seqrite Secure Web Gateway Data Loss Prevention (DLP) Windows & MAC Seqrite Services

Retail / SMB – Drives Scalability

Enterprise Business – Drives Sustainability

Future Opportunities

Turning Problems into Possibilities…

Cybersecurity Predictions

• Threats to become more sophisticated and equipped with advanced AI -led capabilities
• Increase in web skimming attacks
• Projected rise in Ransomware attacks targeting critical infrastructure
• An increase in targeted IoT -based attacks
• Increase in targeted cybercrimes during important public events
• Cryptomining and cloud -based attacks to rise
• Mobile landscape expected to become more threat -prone in 2019
• Rise in targeted attacks to exploit supply chain vulnerabilities
• Attacks on the financial sector to increase
• Data protection to become essential due to data -centric attacks

• Government working on strong data protection regulations
• Enterprises are increasingly adopting security solutions to combat advanced cyber -threats
• Cyber -attacks cost the world \$45 billion in 2018
• Increase in Mobile Transactions : According to RBI data , mobile banking transactions hit 6 ,200 .32 million in 2018 - 19
• Proliferation of smart devices will raise cybersecurity risks . By 2020 , it is anticipated, the IoT may comprise as many as 30 billion devices
• By 2022 , 6 billion people will be vulnerable to cyber -attacks

Q1 FY20 Financials Highlights

Q1 FY20 – Quarterly Consolidated Performance Highlights

* Cash PAT = PAT + Depreciation As per Ind AS

Segment Performance - Revenue Break-up

Segment Performance - Licenses Sold Analysis

	Standalone			Consolidated
PARTICULARS (Rs. mln)	Q1 FY20	Q1 FY19	YoY	Q1 FY20	Q1 FY19	YoY
Total Revenue	571.49	527.88	8.26%	576.00	530.88	8.50%
Direct Cost	27.49	25.48		27.21	23.11
Gross Profit	544.00	502.40	8.28%	548.79	507.77	8.08%
Gross Margin	95.19%	95.17%	+2 bps	95.28%	95.65%	-37 bps
Operating Cost
Research and Development (R&D)	137.90	142.31		137.90	142.31
Sales and Marketing (S&M)	132.05	149.27		135.47	153.50
General Administration (G&A)	143.92	118.10		147.18	122.73
Total Expenditure	413.87	409.67		420.55	418.53
EBITDA	130.13	92.73	40.33%	128.24	89.24	43.70%
EBITDA Margin	22.77%	17.57%	+520 bps	22.26%	16.81%	+545 bps
Depreciation	51.61	59.14		51.63	59.22
EBIT	78.52	33.59	133.76%	76.61	30.02	155.20%
EBIT Margin	13.74%	6.36%	+738 bps	13.30%	5.65%	+765 bps
Other Income	84.27	63.75		84.46	64.09
Profit Before Tax (PBT)	162.79	97.34		161.07	94.11
Tax	41.93	32.93		42.09	32.99
Profit After Tax (PAT)	120.86	64.41	87.64%	118.98	61.12	94.67%
PAT Margin	21.15%	12.20%	+895 bps	20.66%	11.51%	+915 bps

NOTE: Certain figures have been re-grouped wherever necessary

Ratio Analysis

	Standalone		Consolidated
In %	Q1 FY20	Q1 FY19	Q1 FY20	Q1 FY19
Expenses
Direct Cost / Revenue	4.81%	4.83%	4.72%	4.35%
R&D / Revenue	24.13%	26.96%	23.94%	26.81%
S&M / Revenue	23.11%	28.29%	23.52%	28.91%
G&A / Revenue	25.18%	22.37%	25.55%	23.12%
Total Cost / Revenue	72.42%	77.61%	73.01%	78.84%
Margin
Gross Margin	95.19%	95.17%	95.28%	95.65%
EBIDTA	22.77%	17.57%	22.26%	16.81%
EBIT	13.74%	6.36%	13.30%	5.65%
PBT (Before Exceptional Item)	28.49%	18.44%	27.96%	17.73%
PBT (After Exceptional Item)	28.49%	18.44%	27.96%	17.73%
PAT	21.15%	12.20%	20.66%	11.51%

EQUITY AND LIABILITIES (Rs. mln)	June 30, 2018	June 30, 2019
Share Holder's Funds:
Equity Share Capital	704.70	642.01
Reserves and Surplus	6,731.62	5,685.02
Total Shareholder Funds	7,436.32	6,327.03
Non-Current Liabilities
Other Non Current Liabilities	14.65	19.53
Total Non-Current Liabilities	14.65	19.53
Current Liabilities:
Trade and Other Payables	279.39	368.5
Other Financial Liabilities	18.91	33.75
Other Current Liabilities	100.25	122.26
Current tax liabilities (Net)	10.67	13.03
Total Current Liabilities	409.22	537.54
Total Equity & Liabilities	7,860.19	6,884.10

June 30, 2018	June 30, 2019
1567.95	1602.18
131.62	36.63
116.40	63.64
397.69	423.89
3.61	3.75
2.92	3.93
42.93	84.76
65.57	92.83
2,328.69	2,311.61
48.29	36.08
3,014.18	2,044.32
775.04	1028.60
74.19	186.68
1,541.77	1,152.55
8.05	6.33
44.56	46.16
25.42	71.77
5,531.50	4,572.49
7,860.19	6,884.10

NOTE: Certain figures have been re-grouped wherever necessary

EQUITY AND LIABILITIES (Rs. mln)	June 30, 2018	June 30, 2019
Share Holder's Funds:
Equity Share Capital	704.70	642.01
Reserves and Surplus	6,597.98	5,630.50
Total Shareholder Funds	7,302.68	6,272.51
Non-Current Liabilities
Other Non Current Liabilities	14.65	19.53
Total Non-Current Liabilities	14.65	19.53
Current Liabilities:
Trade and Other Payables	283.86	371.60
Other Financial Liabilities	9.45	33.75
Other Current Liabilities	100.32	128.41
Current tax liabilities (Net)	10.84	13.27
Total Current Liabilities	404.47	547.03
Total Equity & Liabilities	7,721.80	6,839.07

ASSETS (Rs mln)	June 30, 2018	June 30, 2019
Non-Current Assets:
Property, plant and equipment	1,568.93	1,602.50
Capital work-in-progress	131.62	36.63
Intangible assets	116.64	63.85
Non-current financial assets
Investments in MF ,Tax-Free Bonds & Subsidiaries	213.19	313.59
Loan and Security Deposits	3.18	3.75
Bank Balances	2.92	3.93
Deferred tax assets (net)	42.96	84.76
Other non current assets	65.88	92.83
Total Non-Current Assets	2,145.32	2,201.84
Current assets:
Inventories	61.70	48.89
Investment in Mutual Fund	3,014.18	2,044.32
Trade and other receivables	770.41	1032.73
Bank Balances & Cash and Cash Equivalents	108.90	233.05
Investment in Fixed Deposit	1,541.77	1,152.55
Loan and security deposits	9.21	7.00
Interest accrued on FDR and Tax-Free Bonds	44.56	46.16
Other Current assets	25.75	72.53
Total Current Assets	5,576.48	4,637.23
Total Assets	7,721.80	6,839.07

NOTE: Certain figures have been re-grouped wherever necessary

Working Capital Analysis

At the end of June 2018*

*Note:

• Debtor days = [(Debtors/ Sales) X (91 days)]
• Inventory days = [(Inventory/Sales) X (91 days)]
• Creditor days = [(Creditor/Sales) X (91 days)]

At the end of March 2019**

**Note:

• Debtor days = [(Debtors/ Sales) X (365 days)]
• Inventory days = [(Inventory/Sales) X (365 days)]
• Creditor days = [(Creditor/Sales) X (365 days)]

At the end of June 2019*

Consolidated Results – Return Ratio Analysis

* Calculated on trailing 12 months basis

Historical Financials Performance

Consolidated Profitability Statement

Particulars (Rs. mln)	FY19	FY18	YoY
Total Revenue	3,149.26	3,183.15	-1.06%
Direct Cost	151.5	167.38
Gross Profit	2,997.76	3,015.77	-0.60%
Gross Margin	95.19%	94.74%	+45 bps
Operating Cost
Research and Development (R&D)	541.22	558.11
Sales and Marketing (S&M)	694.74	735.69
General Administration (G&A)	482.79	518.56
Total Expenditure	1,718.75	1,812.36
EBITDA	1,279.01	1,203.41	6.28%
EBITDA Margin	40.61%	37.81%	+281 bps
Depreciation	235.49	269.27
EBIT	1,043.52	934.14	11.71%
EBIT Margin	33.14%	29.35%	+380 bps
Other Income	326.67	300.02
PBT	1,370.19	1,234.16
Tax	451.95	404.11
PAT	918.24	830.05	10.62%
PAT Margin	29.16%	26.08%	+308 bps

NOTE: Certain figures have been re-grouped wherever necessary

Consolidated Ratio Analysis

In %	FY19	FY18
Expenses
Direct Cost / Revenue	4.81%	5.26%
R&D / Revenue	17.19%	17.53%
S&M / Revenue	22.06%	23.11%
G&A / Revenue	15.33%	16.29%
Total Cost / Revenue	54.58%	56.94%
Margin
Gross Margin	95.19%	94.74%
EBIDTA	40.61%	37.81%
EBIT	33.14%	29.35%
PBT (Before Exceptional Item)	43.51%	38.77%
PBT (After Exceptional Item)	43.51%	38.77%
PAT	29.16%	26.08%

EQUITY AND LIABILITIES (Rs. mln)	31-Mar-19	31-Mar-18	ASSETS (Rs mln)	31-Mar-19	31-Mar-18
Share Holder's Funds:			Non-Current Assets:
Equity Share Capital	705.63	703.88	Property, plant and equipment	1,570.04	1,611.97
Share application money pending allotment	0.17	0.00	Capital work-in-progress	106.33	138.72
Reserves and Surplus	7,191.79	6,534.79	Intangible assets	77.08	118.54
Total Shareholder Funds	7,897.59	7,238.67	Non-current financial assets
			Investments	296.23	175.75
Non-Current Liabilities			Loan and Security Deposits	3.75	3.28
Net employee defined benefit liabilities	18.37	21.04	Bank Balances	4.04	2.92
Other Non Current Liabilities	19.53	0.00	Deferred tax assets (net)	86.69	43.70
Total Non-Current Liabilities	37.90	21.04	Other non current assets	46.06	34.04
Current Liabilities:			Total Non-Current Assets	2,190.22	2,128.92
Trade and Other Payables	387.76	327.06	Current assets:
			Inventories	53.94	56.24
Other Financial Liabilities	34.23	11.99	Investment in Mutual Fund	3,602.17	2,889.04
			Trade and other receivables	1,250.52	1,030.88
Other Current Liabilities	135.87	132.60	Bank Balances & Cash and Cash Equivalents	101.67	122.14
	21.22	13.10	Investment in Fixed Deposit	1,247.33	1,507.24
Net employee defined benefit liabilities			Loans and Security Deposits	7.09	8.72
Current Tax Liabilities (Net)			Interest accured	30.59	39.00
	13.70	62.68	Other Current assets	44.74	24.96
Total Current Liabilities	592.78	547.43	Total Current Assets	6,338.05	5,678.22
Total Equity & Liabilities	8,528.27	7,807.14	Total Assets	8,528.27	7,807.14

		Investments	296.23	175.75
		Inventories	53.94	56.24
		Trade and other receivables	1,250.52	1,030.88
21.22	13.10	Investment in Fixed Deposit	1,247.33	1,507.24
13.70	62.68	Other Current assets	44.74	24.96

NOTE: Certain figures have been re-grouped wherever necessary

Standalone Profitability Statement

Particulars (Rs. mln )	FY19	FY18	YoY
Total Revenue	3,129.03	3,162.22	-1.05%
Direct Cost	153.23	164.43
Gross Profit	2,975.80	2,997.79	-0.73%
Gross Margin	95.10%	94.80%	+30 bps
Operating Cost
Research and Development (R&D)	541.22	558.11
Sales and Marketing (S&M)	674.67	706.18
General Administration (G&A)	465.77	496.19
Total Expenditure	1,681.66	1,760.48
EBITDA	1,294.14	1,237.31	4.59%
EBITDA Margin	41.36%	39.13%	+ 223 bps
Depreciation	235.27	268.82
EBIT	1,058.87	968.49	9.33%
EBIT Margin	33.84%	30.63%	+321 bps
Other Income	325.00	298.75
PBT (Before Exceptional Items)	1,383.87	1,267.24
Exceptional Items	93.17	75.09
PBT (After Exceptional Items)	1290.70	1192.15
Tax	451.06	403.37
PAT	839.64	788.78	6.45%
PAT Margin	26.83%	24.94%	+189 bps

NOTE: Certain figures have been re -grouped wherever necessary

Standalone Ratio Analysis

In %	FY19	FY18
Expenses
Direct Cost / Revenue	4.90%	5.20%
R&D / Revenue	17.30%	17.65%
S&M / Revenue	21.56%	22.33%
G&A / Revenue	14.89%	15.69%
Total Cost / Revenue	53.74%	55.67%
Margin
Gross Margin	95.10%	94.80%
EBIDTA	41.36%	39.13%
EBIT	33.84%	30.63%
PBT (Before Exceptional Items)	44.23%	40.07%
PBT (After Exceptional Items)	41.25%	37.70%
PAT	26.83%	24.94%

Standalone Balance Sheet

EQUITY AND LIABILITIES (Rs. mln)	31-Mar-19	31-Mar-18	ASSETS (Rs mln)	31-Mar-19	31-Mar-18
Share Holder's Funds:			Non-Current Assets:
Equity Share Capital	705.63	703.88	Property, plant and equipment	1,569.69	1,610.96
Share application money pending allotment	0.17	0.00	Capital work-in-progress	106.33	138.72
Reserves and Surplus	7,243.12	6,667.44	Intangible assets	76.86	118.31
Total Shareholder Funds	7,948.92	7,371.32	Non-current financial assets
			Investments	406.53	360.25
Non-Current Liabilities			Loan and Security Deposits	3.75	3.18
Net employee defined benefit liabilities	18.37	21.04	Bank Balances	4.04	2.92
Other non current liabilities	19.53	0.00	Deferred tax assets (net)	86.69	43.70
Total Non-Current Liabilities	37.90	21.04	Non-current tax assets (net)	46.06	34.04
Current Liabilities:			Total Non-Current Assets	2,299.95	2,312.08
Trade and Other Payables	384.83	322.72	Current assets:
			Inventories	41.41	47.15
Other Financial Liabilities	34.23	15.61	Investment in Mutual Fund	3,602.17	2,889.04
			Trade and other receivables	1248.55	1,027.41
Other Current Liabilities	131.49	131.24	Bank Balances & Cash and Cash Equivalents	51.74	83.47
	21.12	13.10	Investment in Fixed Deposit	1,247.33	1,507.24
Net employee defined benefit liabilities			Loans and Security Deposits	6.43	8.13
Current Tax Liabilities (Net)			Interest accured	30.60	39.00
	13.03	62.08	Other Current assets	43.34	23.59
Total Current Liabilities	584.70	544.75	Total Current Assets	6,271.57	5,625.03
Total Equity & Liabilities	8,571.52	7,937.11	Total Assets	8,571.52	7,937.11

		Investments	406.53	360.25
		Inventories	41.41	47.15
		Trade and other receivables	1248.55	1,027.41
21.12	13.10	Investment in Fixed Deposit	1,247.33	1,507.24
13.03	62.08	Other Current assets	43.34	23.59

NOTE: Certain figures have been re-grouped wherever necessary

Shareholding Structure – June 2019

Future Direction

	Plan to push presence in mid-sized market on the back of new and  Enhanced Product enhanced product offerings Offerings Continue to innovate and add new products to the portfolio 
	Offer customised security solutions to organisations across multiple Offer Customised  industries, as well as to explore cross-selling and upselling Solutions opportunities of matured products
Sustain Market Share	On the retail side, our focus will be to sustain the market share in  the retail segment and create a demand for the newly launched Quick Heal Home Security
International Expansion	Focus on international expansions through consistent brand building  and marketing efforts Looking forward towards exploring opportunities in Africa, Middle-East  and South-East Asia.

CIN No: L72200MH1995PLC091408

Company Secretary Mr. Srinivas Anasingaraju [email protected] +91-20-66813232 www.quickheal.co.in

Chief Financial Officer Mr. Nitin Kulkarni [email protected] +91-20-66813232 www.quickheal.co.in

CIN - U74140MH2010PTC204285

Mr. Jigar Kavaiya [email protected] +91 9920602034 www.sgapl.net

THANK YOU!

Sr. No	Name of the Company	Relationship with the Holding Company
	Quick Heal Technologies Japan K.K.	Wholly owned subsidiary
	Quick Heal Technologies America Inc.	Wholly owned subsidiary
3	Quick Heal Technologies Africa Limited	Wholly owned subsidiary
4	Seqrite Technologies DMCC	Wholly owned subsidiary